Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 - MyChesCo
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced recently that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of …
MyChesCo
